CytoSorb 300 mL device

DEVICE3 trials

Sponsors

CytoSorbents, Inc, Imperial College London

Conditions

BleedingCOVID-19Drug RemovalEmergent Cardiothoracic SurgeryHeart Failure

Unknown Phase

Ticagrelor CytoSorb Hemoadsorption

TerminatedNCT04131959

CytoSorbents, IncBleeding, Drug Removal, Emergent Cardiothoracic Surgery

Start: 2019-10-29End: 2021-05-04Updated: 2022-03-09

Registry of CytoSorb Therapy in COVID-19 ICU Patients

CompletedNCT04391920

CytoSorbents, IncCOVID-19

Start: 2020-08-28End: 2022-01-20Updated: 2024-02-09

Role of Cytosorb in Left Ventricular Assist Device Implantation

RecruitingNCT04596813

Imperial College LondonHeart Failure

Start: 2020-09-21End: 2025-06-30Target: 60Updated: 2024-04-18

Related Papers

Extracorporeal hemoadsorption in critically ill COVID-19 patients on VV ECMO: the CytoSorb therapy in COVID-19 (CTC) registry

Critical Care2023-06-1934 citations

CytoSorb Therapy in COVID-19 (CTC) Patients Requiring Extracorporeal Membrane Oxygenation: A Multicenter, Retrospective Registry

Frontiers in Medicine2021-12-2030 citations